INT26736

Context Info Confidence 0.49 First Reported 1986 Last Reported 2009 Negated 0 Speculated 1 Reported most in Abstract Documents 7 Total Number 10 Disease Relevance 3.72 Pain Relevance 2.09

cytosol (Alox5) nuclear envelope (Alox5) oxidoreductase activity (Alox5) nucleus (Alox5) cytoplasm (Alox5)

Anatomy Link Frequency neurons 1 brain 1 astrocytes 1 epithelium 1 Alox5 (Rattus norvegicus)

Pain Link Frequency Relevance Heat Inflammation 96 98.40 cINOD 9 97.88 bradykinin 11 96.80 agonist 2 96.20 antagonist 1 94.68 Analgesic 4 94.24 IPN 2 93.72 Inflammatory mediators 16 89.84 qutenza 3 73.44 ischemia 84 71.72

Disease Link Frequency Relevance Heat Injury 88 98.88 Nociception 2 98.52 INFLAMMATION 127 98.40 Hypersensitivity 2 97.16 Inflammatory Pain 2 93.72 Infarction 32 93.04 Hyperalgesia 1 85.64 Stroke 68 77.92 Cv General 4 Under Development 12 71.72 Cv Unclassified Under Development 52 66.44

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Overall, our results from the Fos-LI and behavior tests suggest that LO products released from inflamed tissues contribute to nociception during carrageenan-induced inflammation, indicating that the LO pathway is a possible target for modulating inflammatory pain.

Localization (released) of LO associated with nociception, inflammation and ipn

1) Confidence 0.49 Published 2009 Journal Mol. Cells Section Abstract Doc Link 19390822 Disease Relevance 0.75 Pain Relevance 0.41

Blockade by lipoxygenase inhibitors of Ca2+-dependent insulin secretion from permeabilized rat islets.

Localization (secretion) of lipoxygenase

2) Confidence 0.49 Published 1989 Journal Biochem. Pharmacol. Section Title Doc Link 2567595 Disease Relevance 0 Pain Relevance 0.05

The decreased relaxation by BK in anococcygeus muscle did not occur by the release of cyclooxygenase products or tachykinins from tracheal epithelium, but it may have occurred by the contractile action of lipoxygenase product secreted by nonepithelial sources.

Localization (secreted) of lipoxygenase in epithelium associated with bradykinin

3) Confidence 0.45 Published 1998 Journal Gen. Pharmacol. Section Abstract Doc Link 9522162 Disease Relevance 0 Pain Relevance 0.46

Co-localization of 5-LOX expression in neurons and microglia/macrophage in brain after IR injury.As inferred from the data above (Fig. 1E, a–c), there is an increase in the expression of 5-LOX enzyme after IR injury.

Localization (localization) of 5-LOX in brain associated with injury

4) Confidence 0.26 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1526713 Disease Relevance 0.54 Pain Relevance 0.06

The critical aspect of 5-LOX/NF-?

Localization (aspect) of 5-LOX

5) Confidence 0.24 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1526713 Disease Relevance 1.00 Pain Relevance 0.27

A co-localization study of 5-LOX and GFAP, a marker for activated astrocytes, showed a few 5-LOX/GFAP positive cells (Fig. 2f).

Localization (localization) of 5-LOX in astrocytes

6) Confidence 0.24 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1526713 Disease Relevance 0.41 Pain Relevance 0.03

To determine the cellular localization of 5-LOX expression, sections from ischemic brain after 24 h of reperfusion were subjected to immunohistochemistry with antibody against 5-LOX. 5-LOX expression co-localized with NSE, a neuron specific marker, implying that 5-LOX protein expression was increased in neurons after IR (Fig. 2c).

Spec (determine) Localization (localization) of 5-LOX in neurons

7) Confidence 0.23 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1526713 Disease Relevance 0.50 Pain Relevance 0.05

In 3-oxo-TA-challenged PMNs, the mitogen-activated protein kinase kinase (MEK)-1/2 inhibitor PD098059 abolished 5-LO product formation, along with inhibition of MEK-1/2 phosphorylation and 5-LO translocation.

Localization (translocation) of 5-LO

8) Confidence 0.05 Published 2001 Journal Mol. Pharmacol. Section Abstract Doc Link 11455013 Disease Relevance 0.06 Pain Relevance 0.06

In our attempt to characterize the stimulating constituents, we identified the tetracyclic triterpene 3-oxo-tirucallic acid (3-oxo-TA), which, in the range from 2.5 to 15 microM, enhanced 5-LO product formation in ionophore-challenged polymorphonuclear cells (PMNs) (e.g., from 1981 +/- 177 to 3042 +/- 208 pmol at 10 microM 3-oxo-TA), and initiated Ca(2+) mobilization, MEK-1/2 phosphorylation, 5-LO translocation, and 5-LO product formation in resting cells (534 +/- 394 pmol/5 x 10(6) PMNs).

Localization (translocation) of 5-LO

9) Confidence 0.05 Published 2001 Journal Mol. Pharmacol. Section Abstract Doc Link 11455013 Disease Relevance 0.08 Pain Relevance 0.08

The acidic NSAID mofebutazone and its metabolite butyl malonic acid mono (1-phenylhydrazide) had no effect on the cardiac release of arachidonic acid-derived cyclo-oxygenase and lipoxygenase products.

Localization (release) of lipoxygenase associated with cinod

10) Confidence 0.03 Published 1986 Journal Agents Actions Suppl. Section Abstract Doc Link 3092600 Disease Relevance 0.38 Pain Relevance 0.61

General Comments

This test has worked.